Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai

Takara Shuzo Co., Inc.

Nippon Shinyaku Company, Ltd.

Bristol-Myers Company

Nippon Kayaku Kabushiki Kaisha

Takara Shuzo Col., Ltd.

Zaidan Hojin Biseibutsu Kagaku

Teruya Nakamura

Tomio Takeuchi

Hamao Umezawa

Akio Fujii

Shinichi Kondo

Katsushige Ikai

Kazutoh Takesako

Daishiro Ikeda

Hironobu Iinuma

Kazuo Shimanaka

Junko Yamamoto

Hideyo Yamaguchi

Fumiyo Haruna

Katsuhisa Uchida

Katsutoshi Takahashi

Akira Obayashi

Yoji Ezure

Yoshihisa Umeda

Masaaki Ishizuka

Tetsushi Saino

Shintaro Suzuki

Fuminori Abe

Shingo Matsumura

Rinzo Nishizawa

Fumihiro Sato

Hamao Umezawa, Deceased

Osamu Tanabe

Nobutoshi Ojima

Taka'aki Ohkuma

Hiroyuki Kuroda

Kiyotaka Konno

Osamu Suzuka

Masao Murayama

Hiroaki Sagawa

Hiroshi Enomoto

Hiromu Murai

Teruhiko Beppu

Masakuni Ozaki

Hirokazu Kotani

Masanobu Kawamata

Makoto Sugiyama

Nobutsugu Hiraoka

Katsuhiko Yamamoto

Makoto Moriguchi

Kyuichi Nemoto

Hisao Watanabe

Masao Yoshida

Akiro Obayashi

Takashi Seto

Susumu Sano

Hideyuki Yasuda

Manabu Itoh

A restriction enzyme is obtained by cultivating a strain of Brevibacterium linens and recovering the restriction enzyme. The restriction enzyme, which has the same specificity as AvrII, cleaves the following nucleotide sequence specifically at the arrow-marked sites: ##STR1##

Restriction enzyme from Brevibacterium linens

An antibiotic R106 represented by the general formula I): ##STR1## wherein: R is methyl or ethyl;

Aureobasidium pullulans which produces antibiotic R106

There are provided R106 compounds represented by the following general formula (I): ##STR1## wherein: A.sub.1 is Phe, o-FPhe, m-FPhe, or Tyr;

R106 compounds

An antibiotic R106 represented by the general formula (I): ##STR1## wherein: R is methyl or ethyl;

Process for the production of antibiotic R106 by a strain of

Novel antibiotics R106

An agent for relieving radiogenic or drug-induced side effects, characterized by comprising a spergualin derivative of the following formula (I):

Method for relieving radiogenic or drug-induced side effects

N-[4-(3-Aminopropyl)aminobutyl]-2-(.omega.-guanidino-fatty acid-amido)-2-substituted-ethanamides represented by the general formula ##STR1## wherein Y represents --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH or ##STR2## R represents a hydrogen atom, an alkyl group of 1 to 4 carbon atoms which may have a hydroxyl group as substituent, or a benzyl group, and n is an integer of from 1 to 8, provided that when Y is ##STR3## and n is 4, R represents the groups other than the hydrogen atom; salt thereof having antitumor activity in experimental animal tumors and a process for the preparation thereof is provided.

N-(4-(3-aminopropyl)aminobutyl)-2-(.omega.-gua

The present invention relates to novel Spergualin-related compounds represented by the general formula [I] ##STR1## (wherein X is ##STR2## R is --H or --CH.sub.2 OH; R.sub.1 is --H, ##STR3## R.sub.2 is a residue obtained by removing, from an amino acid or peptide, the hydroxyl group of the carboxyl group and, when R.sub.1 is a group other than --H, R.sub.2 is same as R.sub.1), or a pharmacologically acceptable salt thereof. Said compounds or salts thereof have an immuno-modulating action.

Novel spergualin-related compounds and process for producing the same

2-amino-2-deoxy-D-mannitol is produced from a microorganism strain of the genus Streptomyces or a mutant strain thereof in improved yields and purity.

Method for manufacturing 2-amino-2-deoxy-D-mannitol

The present invention relates to a stable medical composition for injection containing (1) a Spergualin of the formula: ##STR1## [wherein R is ##STR2## (wherein R' is a lower alkyl group having 1 to 4 carbon atoms), ##STR3## or a salt thereof and (2) at least one stabilizer selected from the group consisting of mannitol, maltose, dextran, lactose, cyclodextrin, gelatin, chondroitin sulfate, and human serum albumin; when R is ##STR4## mannitol is excepted. A spergualin is useful as cancer control agents and immunomodulators.

Medical composition for injection containing a spergualin as active

The present invention relates to an immunosuppressing method which comprises administering a spergualin-related compound represented by the following formula ##STR1## (wherein R.sub.1 is --(CH.sub.2).sub.4 --, --(CH.sub.2).sub.6 --, ##STR2## R.sub.2 is --(CH.sub.2).sub.2 -- or --CH.dbd.CH--; and R.sub.3 is ##STR3## or pharmacologically acceptable salts thereof in an effective amount to a warm-blood animal.

Immunosuppressing method

This invention relates to method for suppressing a transplantation immunity and treating an allergic disease and an autoimmune disease in a mammal which comprises administering spergualin or a pharmaceutically acceptable salt thereof in effective amount to the said mammal.

Method for suppressing a transplantation immunity and treating an

A compound of the formula (I): ##STR1## in which:  is a single bond or a double bond,

Physiologically active substances named SEN-366

The present invention relates to a stable medical composition for injection containing (1) a Spergualin of the formula: ##STR1## [wherein R is ##STR2## --(CH.sub.2).sub.6 --, --(CH.sub.2).sub.4 --CH.dbd.CH--, ##STR3## (wherein R' is a lower alkyl group having 1 to 4 carbon atoms), --(CH.sub.2).sub.8 --, or ##STR4## or a salt thereof and (2) at least one stabilizer selected from the group consisting of mannitol, maltose, dextran, lactose, cyclodextrin, gelatin, chondroitin sulfate, and human serum albumin; when R is ##STR5## mannitol is expected. A spergualin is useful as cancer control agents and immunomodulators.

The feature of the present invention is a process for preparing compounds represented by general formula (Ia) described below: ##STR1## wherein X.sub.1, X.sub.2, X.sub.3, R.sub.1, R.sub.2, R.sub.3 and R.sub.7 are as defined in formula (I) and R.sub.10 represents a lower alkyl group, or acid salts thereof, which process is characterized by using the guanidylfungins (II) as raw materials, reacting these guanidylfungins with alcohols (III) in the presence of an acid catalyst, and then hydrolyzing the malonic acid monoester (IV).

Guanidylfungin derivatives and their production

Growing community of inventors

Kusatsu, Japan

Teruya Nakamura